Journal profile · Hematology
Acta Haematologica
ISSN 0001-5792 · eISSN 1421-9662 · S. Karger AG · SWITZERLAND · Bimonthly · Founded 1948
Acta Haematologica: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 2.91; hybrid open access; median 137 days to acceptance (99 articles, last 24 months); community-reported acceptance: easy; 87 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Acta Haematologica is published by S. Karger AG and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Hemoglobinopathies and Related Disorders, Acute Myeloid Leukemia Research and Chronic Lymphocytic Leukemia Research, together about 23.3% of its articles. Its main subfields are Hematology and Genetics. (generated from OpenAlex topic counts and CAS ranking data)
Since 1948 Acta Haematologica is a well-established and internationally recognized clinically oriented journal featuring balanced, wide-ranging coverage of current hematology research. A wealth of information on such problems as anemia, leukemia, lymphoma, multiple myeloma, hereditary disorders, blood coagulation, growth factors, hematopoiesis, and differentiation is contained in first-rate basic and clinical research papers – some of which are accompanied by editorial comments by eminent experts. These are supplemented by short state-of-the-art communications, reviews, and correspondence as well as occasional special issues devoted to “hot topics” in hematology. Cutting-edge clinical information, along translational research relevant to clinical daily life, will keep the practicing hematologist well informed of the new developments in the field.
From the journal's Aims & Scope
Research area (LetPub): Hematology
Editor-in-chief Pia RaananiPublisher website
Main research topics OpenAlex counts of recent articles; shares are approximate
- Hemoglobinopathies and Related DisordersMedicine9.1%
- Acute Myeloid Leukemia ResearchMedicine7.8%
- Chronic Lymphocytic Leukemia ResearchMedicine6.4%
- Erythrocyte Function and PathophysiologyMedicine6.3%
- Myeloproliferative Neoplasms: Diagnosis and TreatmentMedicine5%
- Diverse Scientific and Economic StudiesEconomics, Econometrics and Finance4.9%
- Blood groups and transfusionMedicine4.9%
- Iron Metabolism and DisordersMedicine4.7%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Hematology | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Hematology | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Hematology | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 2.91LetPub ·
- Impact factor (publisher)
- 2.8Publisher website ·
- CiteScore 2026-06
- 2.9LetPub ·
- CiteScore (publisher)
- 2.9Publisher website ·
- SJR 2026-06
- 0.51LetPub ·
- SNIP 2026-06
- 0.5LetPub ·
- h-index
- 53LetPub ·
- h-index
- 84OpenAlex ·
- i10-index
- 2,862OpenAlex ·
- 2-year mean citedness
- 2OpenAlex ·
- Self-citation rate
- 3.6%LetPub ·
- Share of gold OA articles
- 19.35%LetPub ·
Volume
- Articles per year
- 73LetPub ·
Articles by year OpenAlex count · 8,309 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 38 | 20 | 9 |
| 2025 | 87 | 48 | 124 |
| 2024 | 86 | 36 | 288 |
| 2023 | 98 | 44 | 391 |
| 2022 | 78 | 28 | 385 |
| 2021 | 87 | 29 | 653 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
137 daysMedian, submission to acceptance · P25–P75 93 days – 169 days
- Acceptance to online
- median 20 days (99 articles)
- Submission to online
- median 168 days
- Sample
- 99 articles with submission and acceptance dates (179 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 6–12 weeksLetPub ·
- Average acceptance (community reports)
- EasyLetPub ·
- Acceptance rate (publisher)
- 18.1%Publisher website ·
- Submission to first decision
- 28 daysPublisher website ·
- Submission to final decision
- 49 daysPublisher website ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
No source has fee information yet; check the journal's website.
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- S. Karger AG
- Country or region
- SWITZERLAND
- Language
- English
- Frequency
- Bimonthly
- Founded
- 1948
- ISSN
- 0001-5792
- Electronic ISSN
- 1421-9662
- Latest issue on the website
- Volume 149, Issue 4 (September 2026)
- Official links
- Journal homepage ↗LetPub
- Submission system ↗Publisher website
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Acta Haematologica
What CAS zone is Acta Haematologica in?
In the 2025 upgraded edition of the CAS Journal Ranking, Acta Haematologica is in Zone 4 of Medicine, and in Zone 4 of the minor category Hematology. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Acta Haematologica?
The latest impact factor listed by LetPub is 2.91; CiteScore 2.9, h-index 84.
How long does peer review take at Acta Haematologica?
Based on the dates recorded on 99 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 137 days (interquartile range 93–169 days); authors report an average review time of 6–12 weeks; the community-reported acceptance is “Easy”; the journal's website gives an acceptance rate of 18.1%. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Acta Haematologica?
According to LetPub and DOAJ records, Acta Haematologica is indexed in SCIE and Scopus.
Is Acta Haematologica open access, and what is the APC?
Acta Haematologica is a hybrid journal. Fee information is not available yet; check the journal's website.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .